Biotech Values

[DewDiligence]

SLDB—Cautionary language in S-1 filing (which you already know about):

This is probably the most interesting tidbit from $SLDB S-1

Gene therapy pioneer Penn's James Wilson resigned from Solid's SAB recently citing emerging concerns about possible risks of high systemic dosing of AAV

h/t @MauriceOnTW$ONCE $AVXS $QURE $ABEO $SGMO $BOLD $RGNX $SRPT pic.twitter.com/oT1goHnoW9

— Andy Biotech (@AndyBiotech) January 17, 2018